MEDI 5884

Drug Profile

MEDI 5884

Alternative Names: MEDI5884

Latest Information Update: 22 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shionogi
  • Developer MedImmune
  • Class Cardiovascular therapies; Macromolecular substances
  • Mechanism of Action Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coronary artery disease
  • Phase I Cardiovascular disorders

Most Recent Events

  • 13 Dec 2017 Phase-II clinical trials in Coronary artery disease (In adults, In the elderly, Treatment-experienced) in USA (SC) (NCT03351738)
  • 28 Nov 2017 MedImmune plans a phase II trial for Coronary artery disease (In adults, In the elderly, Treatment-experienced) (SC) (NCT03351738) (CTP#290744)
  • 19 Dec 2016 MedImmune plans a first-in-human phase I trial in Healthy volunteers in USA (SC) (NCT03001297)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top